var data={"title":"Budesonide (oral inhalation): Pediatric drug information \t","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Budesonide (oral inhalation): Pediatric drug information \t</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/771533?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=budesonide-oral-inhalation-drug-information\" class=\"drug drug_general\">see &quot;Budesonide (oral inhalation): Drug information \t&quot;</a> and <a href=\"topic.htm?path=budesonide-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">see &quot;Budesonide (oral inhalation): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663542\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Pulmicort;</li>\n      <li>Pulmicort Flexhaler</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663543\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Pulmicort Turbuhaler</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28673353\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Adrenal Corticosteroid</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Anti-inflammatory Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiasthmatic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Corticosteroid, Inhalant (Oral)</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Glucocorticoid</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28673356\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=budesonide-oral-inhalation-drug-information\" class=\"drug drug_general\">see &quot;Budesonide (oral inhalation): Drug information \t&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatrics:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Asthma:</b> <b>Note:</b> Doses should be titrated to the lowest effective dose once asthma is controlled: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nebulization: Pulmicort Respules: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: Limited data available: Initial: 0.25 mg twice daily or 0.5 mg once daily; maximum daily dose: 1 mg/day (Baker 1999; GINA 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Children &le;8 years or Children &gt;8 years and Adolescents unable to effectively use metered-dose inhalers: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Previously treated with bronchodilators alone: Initial: 0.25 mg twice daily or 0.5 mg once daily; maximum daily dose: 0.5 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Previously treated with inhaled corticosteroids: Initial: 0.25 mg twice daily or 0.5 mg once daily; maximum daily dose: 1 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Previously treated with oral corticosteroids: Initial: 0.5 mg twice daily or 1 mg once daily; maximum daily dose: 1 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Symptomatic children not responding to nonsteroidal asthma medications: Initial: 0.25 mg once daily may be considered </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">NIH Asthma Guidelines (NAEPP 2007): Administer once daily or in divided doses twice daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &le;4 years: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;Low&quot; dose: 0.25 to 0.5 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;Medium&quot; dose: &gt;0.5 to 1 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;High&quot; dose: &gt;1 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 5 to 11 years: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;Low&quot; dose: 0.5 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;Medium&quot; dose: 1 mg/<b>da</b>y </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;High&quot; dose: 2 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral inhalation: Pulmicort Flexhaler: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents age 6 to 17 years: Initial: 180 mcg twice daily (some patients may be initiated at 360 mcg twice daily); maximum single dose: 360 mcg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;18 years: Initial: 360 mcg twice daily (some patients may be initiated at 180 mcg twice daily); maximum single dose: 720 mcg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing: NIH Asthma Guidelines (NAEPP 2007): Administer in divided doses twice daily </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 5 to 11 years: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;Low&quot; dose: 180 to 400 mcg/<b>day</b> (90 mcg/inhalation, 2 to 4 inhalations per day or 180 mcg/inhalation, 1 to 2 inhalations per day) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;Medium&quot; dose: &gt;400 to 800 mcg/<b>day</b> (180 mcg/inhalation, 2 to 4 inhalations per day) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;High&quot; dose: &gt;800 mcg/<b>day</b> (180 mcg/inhalation, &gt;4 inhalations per day) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;Low&quot; dose: 180 to 600 mcg/<b>day</b> (90 mcg/inhalation, 2 to 6 inhalations per day or 180 mcg/inhalation, 1 to 3 inhalations per day) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;Medium&quot; dose: &gt;600 to 1,200 mcg/<b>day</b> (180 mcg/inhalation, 3 to 6 inhalations per day) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;High&quot; dose: &gt;1,200 mcg/<b>day</b> (180 mcg/inhalation, &gt;6 inhalations per day) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conversion from oral systemic corticosteroid to orally inhaled corticosteroid: Initiation of oral inhalation therapy should begin in patients whose asthma is reasonably stabilized on oral corticosteroids (OCS). A gradual dose reduction of OCS should begin ~7 to 10 days after starting inhaled therapy. Manufacturer's labeling recommends reducing prednisone dose by 2.5 mg/day (or equivalent of other OCS) on a weekly basis (patients using oral inhaler) or by &le;25% every 1 to 2 weeks (patients using respules). When transitioning from systemic to inhaled corticosteroids, supplemental systemic corticosteroid therapy may be necessary during periods of stress or during severe asthma attacks. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Asthma:</b> Oral inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: Pulmicort Flexhaler: Initial: 360 mcg twice daily (selected patients may be initiated at 180 mcg twice daily); may increase dose after 1 to 2 weeks of therapy in patients who are not adequately controlled; maximum: 720 mcg twice daily; Note: Doses should be titrated to the lowest effective dose once asthma is controlled. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">NIH Asthma Guidelines (NAEPP 2007): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&quot;Low&quot; dose: 180 to 600 mcg/<b>day</b> (180 mcg/inhalation, 1 to 3 inhalations per day) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&quot;Medium&quot; dose: &gt;600 to 1,200 mcg/<b>day</b> (180 mcg/inhalation, 3 to 6 inhalations per day) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&quot;High&quot; dose: &gt;1,200 mcg/<b>day</b> (180 mcg/inhalation, &gt;6 inhalations per day) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conversion from oral systemic corticosteroid to orally inhaled corticosteroid: Initiation of oral inhalation therapy should begin in patients whose asthma is reasonably stabilized on oral corticosteroids (OCS). A gradual dose reduction of OCS should begin ~7 to 10 days after starting inhaled therapy. Manufacturer's labeling recommends reducing prednisone dose by 2.5 mg/day (or equivalent of other OCS) on a weekly basis (patients using oral inhaler) or by &le;25% every 1 to 2 weeks (patients using respules). When transitioning from systemic to inhaled corticosteroids, supplemental systemic corticosteroid therapy may be necessary during periods of stress or during severe asthma attacks. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Dosage adjustment in renal impairment:</b> Inhalation, Nebulization: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Dosage adjustment in hepatic impairment:</b> Inhalation, Nebulization: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). However, budesonide undergoes hepatic metabolism; drug may accumulate with hepatic impairment; use with caution; monitor closely. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663608\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol Powder Breath Activated, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pulmicort Flexhaler: 90 mcg/actuation (1 ea); 180 mcg/actuation (1 ea) [contains milk protein]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pulmicort: 0.25 mg/2 mL (2 mL); 0.5 mg/2 mL (2 mL); 1 mg/2 mL (2 mL) [contains disodium edta, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.25 mg/2 mL (2 mL); 0.5 mg/2 mL (2 mL); 1 mg/2 mL (2 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663544\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663610\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=budesonide-oral-inhalation-drug-information\" class=\"drug drug_general\">see &quot;Budesonide (oral inhalation): Drug information \t&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Pulmicort Flexhaler 180 mcg/actuation canisters contain 120 actuations and the 90 mcg/actuation canisters contain 60 inhalations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28673357\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nebulization: Shake gently with a circular motion before use. Administer only with a compressed air driven jet nebulizer; do not use an ultrasonic nebulizer; do not mix with other medications; use adequate flow rates and administer via appropriate size face mask or mouthpiece. Avoid exposure of nebulized medication to eyes. Rinse mouth following treatments to decrease risk of oral candidiasis (wash face if using face mask).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral inhaler: Pulmicort Flexhaler: Hold inhaler in upright position (mouthpiece up) to load dose. Do not shake prior to use. Unit should be primed prior to first use. It will not need to be primed again, even if not used for a long time. Place mouthpiece between lips and inhale forcefully and deeply. Do not exhale through inhaler; do not use a spacer. Dose indicator does not move with every dose, usually only after 5 doses. Discard when dose indicator reads &quot;0&quot;. Rinse mouth with water after use to reduce incidence of candidiasis. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663573\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral inhaler (Pulmicort Flexhaler): Store at controlled room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension for nebulization: Store upright at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light. Do not refrigerate or freeze. Once aluminum package is opened, solution should be used within 2 weeks. Continue to protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28673354\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Nebulization: Maintenance therapy and prophylaxis of bronchial asthma (FDA approved in ages 1 to 8 years); <b>not</b> indicated for the relief of acute bronchospasm </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral inhalation: Maintenance therapy and prophylaxis of bronchial asthma with or without oral corticosteroids (FDA approved in ages &ge;6 years and adults); <b>not</b> indicated for the relief of acute bronchospasm </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663563\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Chest pain (suspension), syncope (powder)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Emotional lability (suspension), fatigue (suspension), headache, hypertonia (powder), insomnia (powder), pain (powder), voice disorder (powder), </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Contact dermatitis (suspension), eczema (suspension), pruritus (suspension), pustular rash (suspension), skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Weight gain </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, anorexia (suspension), diarrhea (suspension), dysgeusia (powder), dyspepsia, gastroenteritis (suspension), nausea, oral candidiasis (powder), viral gastroenteritis (powder), vomiting, xerostomia (powder)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Cervical lymphadenopathy (suspension), ecchymosis (powder), purpura (suspension) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Candidiasis (suspension), herpes simplex infection (suspension), infection, viral infection (suspension)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, back pain (powder), bone fracture, hyperkinesia (suspension), myalgia, neck pain (powder), weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Conjunctivitis (suspension), eye infection (suspension) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Otalgia (suspension), otic infection (suspension), otitis externa (suspension), otitis media (more common in suspension) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Allergic rhinitis (powder), cough, epistaxis (suspension), flu-like symptoms (suspension), nasal congestion (powder), nasopharyngitis (powder), pharyngitis, respiratory infection (more common in suspension), respiratory tract infection (powder), rhinitis, sinusitis, stridor (suspension), viral upper respiratory tract infection (powder) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Rare but important or life-threatening: Adrenocortical insufficiency, aggressive behavior, anxiety, avascular necrosis of femoral head, bronchitis, bruise, depression, glaucoma, growth suppression, hypercorticoidism, increased intraocular pressure, irritability, nervousness, osteoporosis, pain, pharyngitis, psychosis, throat irritation, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663558\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to budesonide or any component of the formulation; severe hypersensitivity to milk proteins (Pulmicort Flexhaler); primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive measures</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Moderate-to-severe bronchiectasis, pulmonary tuberculosis (active or quiescent), untreated respiratory infection (bacterial, fungal, or viral)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663559\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children, in patients receiving high doses for prolonged periods, or with concomitant CYP3A4 inhibitor use. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products or corticosteroids with lower systemic effect due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Adult patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do <b>not</b> provide the systemic steroid needed to treat patients having trauma, surgery, or infections. Do not use this product to transfer patients directly from oral corticosteroid therapy. Select surgical patients on long-term, high-dose, inhaled corticosteroid (ICS), should be given stress doses of hydrocortisone intravenously during the surgical period and the dose reduced rapidly within 24 hours after surgery (NAEPP 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchospasm: May occur with wheezing after inhalation; if this occurs stop steroid and treat with a fast-acting bronchodilator (eg, albuterol).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox should be avoided; corticosteroids should not be used to treat ocular herpes simplex. Corticosteroids should not be used for viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Local oral infections: <i>Candida albicans</i> infections may occur in the mouth and pharynx; rinsing (and spitting) with water after inhaler use may decrease risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myopathy: Acute myopathy has been reported with high-dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Preexisting psychiatric conditions may be exacerbated by corticosteroid use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Supplemental steroids (oral or parenteral) may be needed during stress or severe asthma attacks. Not to be used in status asthmaticus or for the relief of acute bronchospasm.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone mineral density: Use with caution in patients with major risk factors for decreased bone mineral count such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (eg, anticonvulsants or oral corticosteroids); long-term use of inhaled corticosteroids have been associated with decreases in bone mineral density.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with HF or hypertension; long-term use has been associated with fluid retention and hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to perforation risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention. Increased oral bioavailability has been reported in patients with cirrhosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myocardial infarction: Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in chronic users.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vasculitis: Rare cases of vasculitis (eosinophilic granulomatosis with polyangiitis [formerly known as Churg-Strauss]) or other systemic eosinophilic conditions can occur; often associated with decrease and/or withdrawal of oral corticosteroid therapy following initiation of inhaled corticosteroid.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Orally-inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range 0.3 to 1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of orally-inhaled corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose: Pulmicort Flexhaler contains lactose; very rare anaphylactic reactions have been reported in patients with severe milk protein allergy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Withdraw systemic therapy with gradual tapering of dose. There have been reports of systemic corticosteroid withdrawal symptoms (eg, joint/muscle pain, lassitude, depression) when withdrawing oral inhalation therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44312147\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;\">A 12-week study in infants (n=141; 6 to 12 months of age) receiving budesonide nebulizations (0.5 mg or 1 mg once daily) vs placebo demonstrated a budesonide dose dependent suppression of linear growth; in addition, although mean changes from baseline did not indicate budesonide-induced adrenal suppression, six infants who received budesonide had subnormal stimulated cortisol levels at week 12. Children and adolescents (n=18; 6 to 15 years) receiving budesonide nebulizations of 1 and 2 mg twice daily showed a significant reduction in urinary cortisol excretion; this reduction was not seen when patients were dosed at 1 mg/day (maximum recommended dose). Long-term effects of chronic use of budesonide nebulization on immunological or developmental processes of upper airways, mouth, and lung are unknown. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663568\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663565\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=104951&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Budesonide (Oral Inhalation).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Corticosteroids (Orally Inhaled) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Budesonide (Oral Inhalation). Management: Concomitant use of these agents is not recommended, unless the risk for excessive systemic corticosteroid effects is outweighed by the potential benefits. If combined, monitor patients closely for signs and symptoms of corticosteroid excess/toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663553\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (inhalation) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663554\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed with corticosteroids in animal reproduction studies. Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts (Park-Wyllie 2000; Pradat 2003). Systemic corticosteroids may also influence fetal growth (decreased birth weight); however, information is conflicting (Lunghi 2010). Hypoadrenalism may occur in newborns following maternal use of corticosteroids in pregnancy; monitor. When systemic corticosteroids are needed in pregnancy, it is generally recommended to use the lowest effective dose for the shortest duration of time, avoiding high doses during the first trimester (Leachman 2006; Lunghi 2010). Budesonide may be used for the induction of remission in pregnant women with inflammatory bowel disease (Habal 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Based on available data, an overall increased risk of congenital malformations or a decrease in fetal growth has not been associated with maternal use of inhaled corticosteroids during pregnancy (Bakhireva 2005; NAEPP 2005; Namazy 2004). In addition, studies of pregnant women specifically using inhaled budesonide have not demonstrated an increased risk of congenital abnormalities. Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, pre-eclampsia, preterm birth, low birth weight infants). Inhaled corticosteroids are recommended for the treatment of asthma during pregnancy; budesonide is preferred (ACOG 2008; NAEPP 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28673358\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor growth in pediatric patients; inhalation: Check mucous membranes for signs of fungal infection; Asthma: FEV<sub>1</sub>, peak flow, and/or other pulmonary function tests; long-term use: Regular eye examinations and IOP, blood pressure, glucose, signs and symptoms of hypercorticism, or adrenal suppression. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663574\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Controls the rate of protein synthesis; depresses the migration of polymorphonuclear leukocytes, fibroblasts; reverses capillary permeability and lysosomal stabilization at the cellular level to prevent or control inflammation. Has potent glucocorticoid activity and weak mineralocorticoid activity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663576\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Nebulization: 2 to 8 days; Inhalation: 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: Nebulization: 4 to 6 weeks; Inhalation: 1 to 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 4 to 6 years: 3 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 2.2 to 3.9 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 85% to 90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via CYP3A4 to two metabolites: 16 alpha-hydroxyprednisolone and 6 beta-hydroxybudesonide; both are &lt;1% as active as parent</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nebulization: Children 4 to 6 years: 6%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral inhalation: 39% of an inhaled metered dose is available systemically</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 4 to 6 years: 2.3 hours (after nebulization)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents 10 to 14 years: 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 2 to 3.6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nebulization: Pulmicort Respules: Children: 20 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral inhalation: Pulmicort Flexhaler: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children and Adolescents: 15 to 30 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (60%) and feces as metabolites </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 4 to 6 years: 0.5 L/minute (~50% greater than healthy adults after weight adjustment) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 0.9 to 1.8 L/minute </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46679384\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Oral budesonide viscous liquid/suspension:</b> Prepare immediately prior to ingestion from aqueous budesonide solution (1 mg per 2 mL) or nebulized solution (0.5 mg per 2 mL [Pulmicort Respules]) mixed to slurry consistency with 10 packets of Splenda or 2.5 cm<sup>3</sup> of Neocate Nutra per milligram of budesonide. (Dellon 2013; Dohil 2010; Rubinstein 2014)</p>\n    <div class=\"reference\">Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras CA, Katzka DA; American College of Gastroenterology. ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). <i>Am J Gastroenterol</i>. 2013 May;108(5):679-92; quiz 693.<span class=\"pubmed-id\">23567357</span></div>\r\n\n    <div class=\"reference\">Dohil R, Newbury R, Fox L, Bastian J, Aceves S. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. <i>Gastroenterology</i>. 2010;139(2):418-429.<span class=\"pubmed-id\">20457157</span></div>\r\n\n    <div class=\"reference\">Rubinstein E, Lee JJ, Fried A, et al. Comparison of 2 delivery vehicles for viscous budesonide to treat eosinophilic esophagitis in children. <i>J Pediatr Gastroenterol Nutr</i>. 2014;59(3):317-320.<span class=\"pubmed-id\">24821535</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663613\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (Pulmicort Flexhaler Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mcg/ACT (1): $205.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mcg/ACT (1): $275.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Budesonide Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg/2 mL (2 mL): $9.41</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg/2 mL (2 mL): $11.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/2 mL (2 mL): $12.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Pulmicort Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg/2 mL (2 mL): $10.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg/2 mL (2 mL): $12.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/2 mL (2 mL): $24.62</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45649865\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aeronide (TH);</li>\n      <li>Aerovent (AR);</li>\n      <li>Aircort (MT);</li>\n      <li>B Cort (CO);</li>\n      <li>Benita (VN);</li>\n      <li>Budecort (MY, VN);</li>\n      <li>Budenocort (NZ);</li>\n      <li>Budeson (AR, BD);</li>\n      <li>Budiair Jet (BG);</li>\n      <li>Busonid (BR);</li>\n      <li>Denecort (PH);</li>\n      <li>Duasma HFA (HK);</li>\n      <li>Frenolyn (SG, TR);</li>\n      <li>Giona Easyhaler (SG, TH);</li>\n      <li>Inflammide (PE);</li>\n      <li>Miflonid (CZ);</li>\n      <li>Miflonide (AT, BE, CL, DE, DK, EC, EE, ES, IL, IT, NZ, PT, TR);</li>\n      <li>Neumocort (PY);</li>\n      <li>Novopulmon (DE, FR);</li>\n      <li>Numark (MX);</li>\n      <li>Pulmax (ZA);</li>\n      <li>Pulmicort (AE, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CY, CZ, DK, EE, EG, FI, FR, GB, GR, HK, HU, ID, IE, IN, IS, JO, JP, KR, KW, LB, LU, LV, MX, NL, NO, NZ, PK, PL, PT, QA, RO, RU, SA, SE, SG, SK, TH, TR, TW, UA, UY, VE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-pediatric-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Asthma In Pregnancy,&rdquo; ACOG Practice Bulletin No. 90. American College of Obstetricians and Gynecologists, <i>Obstet Gynecol</i>, 2008, 111(2 Pt 1):457-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-pediatric-drug-information/abstract-text/18238988/pubmed\" target=\"_blank\" id=\"18238988\">18238988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baker JW, Mellon M, Wald J, et al, &quot;A Multiple-Dosing, Placebo-Controlled Study of Budesonide Inhalation Suspension Given Once or Twice Daily for Treatment of Persistent Asthma in Young Children and Infants,&quot; <i>Pediatrics</i>, 1999, 103(2):414-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-pediatric-drug-information/abstract-text/9925834/pubmed\" target=\"_blank\" id=\"9925834\">9925834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bakhireva LN, Jones KL, Schatz M, et al, &ldquo;Asthma Medication Use in Pregnancy and Fetal Growth,&rdquo; <i>J Allergy Clin Immunol</i>, 2005, 116(3):503-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-pediatric-drug-information/abstract-text/16159616/pubmed\" target=\"_blank\" id=\"16159616\">16159616</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-pediatric-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      From the Global Strategy for the Diagnosis and Management of Asthma in Children 5 Years and Younger, Global Initiative for Asthma (GINA) 2009. Available at http://www.ginasthma.org/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Habal FM and Huang VW, &quot;Review Article: A Decision-Making Algorithm For the Management of Pregnancy in the Inflammatory Bowel Disease Patient,&quot; <i>Aliment Pharmacol Ther</i>, 2012, 35(5):501-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-pediatric-drug-information/abstract-text/22221203/pubmed\" target=\"_blank\" id=\"22221203\">22221203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatiti</i>s. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-pediatric-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leachman SA and Reed BR, &quot;The Use of Dermatologic Drugs in Pregnancy and Lactation,&quot; <i>Dermatol Clin</i>, 2006, 24(2):167-97, vi.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-pediatric-drug-information/abstract-text/16677965/pubmed\" target=\"_blank\" id=\"16677965\">16677965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-pediatric-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lunghi L, Pavan B, Biondi C, et al, &quot;Use of Glucocorticoids in Pregnancy,&quot;<i> Curr Pharm Des</i>, 2010, 16(32):3616-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-pediatric-drug-information/abstract-text/20977425/pubmed\" target=\"_blank\" id=\"20977425\">20977425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP), &quot;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&quot; Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at <a href=\"http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NAEPP Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at <a href=\"http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Namazy J, Schatz M, Long L, et al, &ldquo;Use of Inhaled Steroids by Pregnant Asthmatic Women Does Not Reduce Intrauterine Growth,&rdquo; <i>J Allergy Clin Immunol</i>, 2004, 113(3):427-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-pediatric-drug-information/abstract-text/15007341/pubmed\" target=\"_blank\" id=\"15007341\">15007341</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park-Wyllie L, Mazzotta P, Pastuszak A, et al, &quot;Birth Defects After Maternal Exposure to Corticosteroids: Prospective Cohort Study and Meta-Analysis of Epidemiological Studies,&quot; <i>Teratology</i>, 2000, 62(6):385-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-pediatric-drug-information/abstract-text/11091360/pubmed\" target=\"_blank\" id=\"11091360\">11091360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pradat P, Robert-Gnansia E, Di Tanna GL, et al, &ldquo;First Trimester Exposure to Corticosteroids and Oral Clefts,&rdquo; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(12):968-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-pediatric-drug-information/abstract-text/14745915/pubmed\" target=\"_blank\" id=\"14745915\">14745915</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pulmicort Flexhaler aerosol, powder (budesonide) [prescribing information]. Wilmington, DE: AstraZeneca LP; July 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pulmicort Respules suspension (budesonide) [prescribing information]. Wilmington, DE: AstraZeneca LP; July 2010. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-pediatric-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Szefler SJ, &quot;A Review of Budesonide Inhalation Suspension in the Treatment of Pediatric Asthma,&quot; <i>Pharmacotherapy</i>, 2001, 21(2):195-206.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-pediatric-drug-information/abstract-text/11213857/pubmed\" target=\"_blank\" id=\"11213857\">11213857</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 104951 Version 43.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F28663542\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F28663543\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F28673353\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F28673356\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F28663608\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F28663544\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F28663610\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F28673357\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F28663573\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F28673354\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F28663563\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F28663558\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F28663559\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F44312147\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F28663568\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F28663565\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F28663553\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F28663554\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F28673358\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F28663574\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F28663576\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F46679384\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F28663613\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F45649865\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/104951|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=budesonide-oral-inhalation-drug-information\" class=\"drug drug_general\">Budesonide (oral inhalation): Drug information \t</a></li><li><a href=\"topic.htm?path=budesonide-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">Budesonide (oral inhalation): Patient drug information \t</a></li></ul></div></div>","javascript":null}